CING

Cingulate, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website cingulate.com
Employees(FY) 15
ISIN US17248W2044

Performance

-9.39%

1W

-1.0%

1M

-30.87%

3M

-86.22%

6M

-89.52%

YTD

-95.78%

1Y

Profile

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Advanced Technical Analysis

Technical Analysis of CING 2024-05-10

Overview:

In the last 5 trading days, CING stock has shown a downward trend in both price and volume. The moving averages (MA) have been declining, indicating a bearish trend. Momentum indicators like RSI and Stochastic oscillators suggest the stock is oversold. Volatility indicators show a narrowing Bollinger Band, indicating decreased price vo...

See more ...

Recent News & Updates

2024-05-08 01:54
CING Stock Earnings: Cingulate Beats EPS for Q1 2024(Investorplace)
2024-05-07 19:00
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update(Globenewswire)
2024-04-29 17:45
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access(Globenewswire)
2024-04-28 21:00
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV(Accesswire)
2024-04-16 05:00
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024(Globenewswire)
2024-03-31 20:00
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update(Globenewswire)
2024-03-19 04:45
Cingulate to Participate in Benzinga All Live Access Event(Globenewswire)
2024-03-05 17:45
Cingulate to Attend DCAT Week 2024 in New York City(Globenewswire)
2024-02-12 17:45
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors(Globenewswire)
2024-02-06 03:15
Cingulate Announces Closing of $7.5 Million Public Offering(Globenewswire)
2024-02-01 20:15
Cingulate Announces Pricing of $7.5 Million Public Offering(Globenewswire)
2024-01-28 19:00
Longtime Cingulate Controller Jennifer Callahan Promoted to CFO(Globenewswire)
2024-01-28 17:45
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market(Globenewswire)
2023-12-27 21:15
Why Is Cingulate (CING) Stock Up 160% Today?(Investorplace)
2023-12-05 18:00
Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now(Globenewswire)
2023-12-04 18:00
Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now(Globenewswire)
2023-11-30 20:00
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)(Globenewswire)
2023-11-13 03:15
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update(Globenewswire)
2023-10-30 19:00
Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now(Globenewswire)
2023-10-17 02:22
Cingulate to Host CNS Key Opinion Leader Panel in New York City(Globenewswire)
2023-09-21 01:30
Cingulate Inc. to Present at the LD Micro Main Event XVI(Yahoo Finance)
2023-09-14 19:58
Cingulate raises $4M from public offering of almost 7M shares(Yahoo Finance)
2023-09-13 04:15
Cingulate Announces Closing of $4.0 Million Public Offering(Yahoo Finance)
2023-09-10 21:22
Cingulate Announces Pricing of $4.0 Million Public Offering(Yahoo Finance)
2023-09-10 18:00
Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD(Yahoo Finance)
2023-09-08 04:31
Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium(Yahoo Finance)
2023-09-04 20:00
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023(Yahoo Finance)
2023-08-14 04:15
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update(Yahoo Finance)
2023-07-26 18:25
Cingulate Slides As Insider Purchases Lose Another US$45k(Yahoo Finance)
2023-07-10 20:00
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD(Yahoo Finance)

Page 1 of 3

previousnext